IN THE CLAIMS:

Please amend the claims as follows:

Please replace "Claims" with WE CLAIM: .

- 1. (amended) A drug composition to be applied topically for promoting the regeneration of tissue, characterized in that—it contains comprising microparticles from blood cells and/or tissues which have been purified by a process selected from the group consisting of differential centrifugation, filtration of and affinity chromatography, it—wherein the drug composition has been subjected to a procedure for selected from the group consisting of virus inactivation and or virus depletion,—it—has been prepared under sterile conditions, and—it is provided in a state selected from the group consisting of a freeze-dried state and a of deep-frozen state.
- 2. (amended) A drug composition according to claim 1, characterized in that it contains comprising soluble or insoluble substances promoting wound healing.
- 3. (amended) A drug composition according to claim 1 or claim 2, characterized in that it contains comprising cytokines and/or growth factors.
- 4. (amended) A drug composition according to <u>claim 1</u> any of <u>claims 1</u> to 3, <u>characterized in</u> that it contains <u>comprising</u> a substance which constitutes or may form a provisional extracellular matrix.
- 5. (amended) A drug composition according to <u>claim 1</u> any of claims 1 to 4, characterized in that it contains <u>comprising</u> collagen.
- 6.(amended) A drug composition according to <u>claim 1</u> any of claims 1 to 5, characterized in that it contains comprising fibrinogen and thrombin for the formation of a fibrin scaffold.

NY02:449928.1 4

A35931-PCT-USA-A - 071986.0249

PATENT

- 7. (amended) A drug composition according to claim 4, characterized in that wherein an organic polymer, in particular a polyacton is used as the provisional extracellular matrix.
- 8. (amended) A drug composition according to <u>claim 1</u> any of claims 1 to 7, characterized in that it contains <u>comprising</u> inorganic compounds.
- 9. (amended) A drug product characterized in that it exhibits comprising
 - a drug composition according to any of claims 1 to 8 and
 - a biocompatible material which is applied together with the drug composition.
- 10. (amended) A drug product according to claim 9, characterized in that wherein the biocompatible material is selected from the group consisting of titanium or and an apatite.
- 11. (amended) A process for promoting the regeneration of tissue, in particular the regeneration of bone tissue, characterized in that wherein a drug composition according to any of claims 1 to 8 is applied together with a biocompatible material in particular titanium or an apatite.
- 12. (amended) The use of an aqueous suspension which contains virus inactivated microparticles from blood cells and/or tissues for the preparation of a drug composition A method for accelerating cell growth, in particular the growth of osteoclasts comprising administering, to a cell, an aqueous suspension comprising virus-inactivated microparticles from a source selected from the group consisting of blood cells, tissues, and a combination thereof.
- 13. (new) The drug composition of claim 7, wherein the organic polymer is a polyacton.
- 14. (new) The process of claim 11, wherein the tissue in which regeneration is promoted is bone tissue.

NY02:449928.1 5

A35931-PCT-USA-A - 071986.0249

PATENT

- 15. (new) The process of claim 11, wherein the biocompatible material is selected from the group consisting of titanium and an apatite.
- 16. (new) The process of claim 12, in which cell growth is accelerated in osteoclasts.

NY02:449928.1 6